278 related articles for article (PubMed ID: 25556056)
1. Effects of topical corticosteroids on cell proliferation, cell cycle progression and apoptosis: in vitro comparison on HaCaT.
Guichard A; Humbert P; Tissot M; Muret P; Courderot-Masuyer C; Viennet C
Int J Pharm; 2015 Feb; 479(2):422-9. PubMed ID: 25556056
[TBL] [Abstract][Full Text] [Related]
2. The effects of betamethasone dipropionate and fish oil on HaCaT proliferation and apoptosis.
Zulfakar MH; Ong CM; Heard CM
Int J Pharm; 2012 Sep; 434(1-2):399-405. PubMed ID: 22692079
[TBL] [Abstract][Full Text] [Related]
3. Effects of corticosteroids on the growth and metabolism of fibroblasts cultured from human skin.
Priestley GC
Br J Dermatol; 1978 Sep; 99(3):253-61. PubMed ID: 81679
[TBL] [Abstract][Full Text] [Related]
4. Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilising the human skin blanching assay.
Meyer E; Smith EW; Haigh JM; Kanfer I
Arzneimittelforschung; 1988 Dec; 38(12):1840-3. PubMed ID: 3245859
[TBL] [Abstract][Full Text] [Related]
5. Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo.
Serup J; Holm P
Dermatologica; 1985; 170(4):189-94. PubMed ID: 3888708
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of beneficial and adverse effects of glucocorticoids on a newly developed full-thickness skin model.
Zöller NN; Kippenberger S; Thaçi D; Mewes K; Spiegel M; Sättler A; Schultz M; Bereiter-Hahn J; Kaufmann R; Bernd A
Toxicol In Vitro; 2008 Apr; 22(3):747-59. PubMed ID: 18249522
[TBL] [Abstract][Full Text] [Related]
7. Discrimination of the toxic potential of chemically differing topical glucocorticoids using a neutral red release assay with human keratinocytes and fibroblasts.
Korting HC; Hülsebus E; Kerscher M; Greber R; Schäfer-Korting M
Br J Dermatol; 1995 Jul; 133(1):54-9. PubMed ID: 7669640
[TBL] [Abstract][Full Text] [Related]
8. Objective assessment of topical corticosteroids and non-steroidal anti-inflammatory drugs in methyl-nicotinate-induced skin inflammation.
Duteil L; Queille C; Poncet M; Ortonne JP; Czernielewski J
Clin Exp Dermatol; 1990 May; 15(3):195-9. PubMed ID: 2364573
[TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory potency testing of topical corticosteroids and calcineurin inhibitors in human volunteers sensitized to diphenylcyclopropenone.
Mose KF; Andersen F; Røpke MA; Skov L; Friedmann PS; Andersen KE
Br J Clin Pharmacol; 2018 Aug; 84(8):1719-1728. PubMed ID: 29607554
[TBL] [Abstract][Full Text] [Related]
10. Epidermal cell DNA content and intermediate filaments keratin 10 and vimentin after treatment of psoriasis with calcipotriol cream once daily, twice daily and in combination with clobetasone 17-butyrate cream or betamethasone 17-valerate cream: a comparative flow cytometric study.
Glade CP; Van Erp PE; Van De Kerkhof PC
Br J Dermatol; 1996 Sep; 135(3):379-84. PubMed ID: 8949429
[TBL] [Abstract][Full Text] [Related]
11. Are the Spanish baseline series markers sufficient to detect contact allergy to corticosteroids in Spain? A GEIDAC prospective study.
Mercader-García P; Pastor-Nieto MA; García-Doval I; Giménez-Arnau A; González-Pérez R; Fernández-Redondo V; Serra-Baldrich E; Cordoba-Guijarro S; Gatica-Ortega ME; Silvestre-Salvador JF;
Contact Dermatitis; 2018 Jan; 78(1):76-82. PubMed ID: 28960334
[TBL] [Abstract][Full Text] [Related]
12. Diflucortolone valerate (Nerisona): a comparative vasoconstriction test in artificially induced hyperemia of the skin.
Reckers R; Wendt H
Clin Ther; 1980; 3(3):190-3. PubMed ID: 7459929
[TBL] [Abstract][Full Text] [Related]
13. Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay.
Borelli C; Gassmueller J; Fluhr JW; Nietsch KH; Schinzel S; Korting HC
Skin Pharmacol Physiol; 2008; 21(3):181-7. PubMed ID: 18523415
[TBL] [Abstract][Full Text] [Related]
14. The dilution of proprietary corticosteroid ointments--an attempt to evaluate relative clinical potencies.
Gibson JR; Darley C; Kirsch J; Saihan EM; Neild VS
Br J Dermatol; 1982 Apr; 106(4):445-7. PubMed ID: 7073968
[TBL] [Abstract][Full Text] [Related]
15. The effects of betamethasone derivatives on endotoxin-induced uveitis in rats.
Tsuji F; Sawa K; Kato M; Mibu H; Shirasawa E
Exp Eye Res; 1997 Jan; 64(1):31-6. PubMed ID: 9093018
[TBL] [Abstract][Full Text] [Related]
16. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use.
Brazzini B; Pimpinelli N
Am J Clin Dermatol; 2002; 3(1):47-58. PubMed ID: 11817968
[TBL] [Abstract][Full Text] [Related]
17. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.
Menter A; Abramovits W; Colón LE; Johnson LA; Gottschalk RW
J Drugs Dermatol; 2009 Jan; 8(1):52-7. PubMed ID: 19180896
[TBL] [Abstract][Full Text] [Related]
18. A comparison of clobetasol propionate 0.05 percent ointment and an optimized betamethasone dipropionate 0.05 percent ointment in the treatment of psoriasis.
Jacobson C; Cornell RC; Savin RC
Cutis; 1986 Mar; 37(3):213-4, 216, 218-20. PubMed ID: 3514155
[TBL] [Abstract][Full Text] [Related]
19. Fitting Pharmacodynamic Data to the
Tapfumaneyi P; Rath S; Bon C; Kanfer I
Mol Pharm; 2022 Aug; 19(8):2900-2906. PubMed ID: 35763717
[TBL] [Abstract][Full Text] [Related]
20. Effects of mometasone furoate on human keratinocytes and fibroblasts in vitro.
Wach F; Bosserhoff A; Kurzidym U; Nowok K; Landthaler M; Hein R
Skin Pharmacol Appl Skin Physiol; 1998; 11(1):43-51. PubMed ID: 9603668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
